Regulate cancer cell apoptosis with ABT-263, a chemotherapeutic agent and an inhibitor of B cell lymphoma 2 (Bcl-2), B cell lymphoma-extra large (Bcl-xL), and Bcl-2-like protein 2 (Bcl-W) (Ki = < 1 nM, < 0.5, and < 1 nM, respectively). Bcl-2 and Bcl-xL are anti-apoptotic proteins that regulate cell death by interacting with pro-apoptotic proteins, like Bcl-2-like protein 11 (BIM), to induce or inhibit apoptosis (Tse et al.). ABT-263 displaces Bcl-xL from binding to BIM, allowing cells to undergo apoptosis (Lagares et al.).

ABT-263 has been used for:

IMMUNOLOGY
· Reduces expression of mitochondrial antiviral signaling protein (MAVS) in macrophages (Kim et al.).
· Induces apoptosis in influenza A virus-infected cells by activating the caspase 9-mediated mitochondrial apoptosis pathway (Kakkola et al.).
CANCER RESEARCH
· Inhibits tumor growth in small cell lung cancer xenograft models (Aguilar et al.).
· Acts as a selective senolytic in vitro by inducing apoptosis in senescent tumor cells after induction into senescence by chemotherapy or radiation (Saleh et al.).
· Promotes apoptosis in senescent murine Lewis lung carcinoma (LLC) cells (Saleh et al.).
· Induces G1/G0-phase arrest, apoptosis, and autophagy in human esophageal cancer cells (EC109, HKESC-2, and CaES-17) in vitro (Lin et al.).